-
Mashup Score: 46
Bone Marrow Transplantation – Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT
Source: www.nature.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 46
Bone Marrow Transplantation – Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT
Source: www.nature.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 13Alloengraftment without significant toxicity or GVHD in CD45 antibody-drug conjugate conditioned Fanconi anemia mice - 3 month(s) ago
Key Points. Pretransplant single dose CD45-ADC conditioning effectively promoted alloengraftment with low toxicity in 3 Fanconi anemia mouse models.Donor T cell
Source: ashpublications.orgCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 26Early CAR-T Cells expansion is associated with prolonged PFS for patients with RRMM treated with ide-cel: a retrospective monocentric study. - 3 month(s) ago
The outcome of patients with relapsed and refractory multiple myeloma (RRMM) previously treated with the three main classes of myeloma therapy [immunomodulatory drugs (Imids), proteasome inhibitors (PI), and anti-CD38 antibodies (anti-CD38)] remains poor. However, in the KarMMa trial1, the use of idecabtagene vicleucel (ide-cel), an autologous B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell therapy (CAR-T) showed improved response with prolonged overall survival (OS) and progression-free survival (PFS) among heavily treated patients.
Source: www.astctjournal.orgCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 45
Bone Marrow Transplantation – Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT
Source: www.nature.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 6Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy - 3 month(s) ago
With a median follow-up of 63.6 months, mPFS of patients aged ≥60 years with cHL treated with upfront BV-DTIC was 47.2 months.Noncomparatively, mPFS of patients
Source: ashpublications.orgCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 37Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium - 3 month(s) ago
BT does not have a significant influence on response rates, progression-free survival, and overall survival for patients who receive axi-cel.BT with radiation r
Source: ashpublications.orgCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 6Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy - 3 month(s) ago
With a median follow-up of 63.6 months, mPFS of patients aged ≥60 years with cHL treated with upfront BV-DTIC was 47.2 months.Noncomparatively, mPFS of patients
Source: ashpublications.orgCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 2
Nature – A high baseline of intratumoural macrophages and regulatory T cells is associated with better outcomes in patients with non-small cell lung cancer treated with atezolizumab plus…
Source: www.nature.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 12Reinfusion of CD19 CAR T Cells for Relapse Prevention and Treatment in Children with Acute Lymphoblastic Leukemia - 3 month(s) ago
Key Points. Reinfusion extended CAR T cell persistence in 52% of patients reinfused for relapse prevention, thereby potentially reducing relapse risk.Reinfusion
Source: ashpublications.orgCategories: General Medicine News, Hematologists1Tweet
Trends in #HCT and #CART in 2022. HCT decreases, CART goes up https://t.co/H6kBJb5cPK